| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 46 | 2024 | 4239 | 4.030 |
Why?
|
| Testicular Neoplasms | 18 | 2024 | 799 | 3.660 |
Why?
|
| Carcinoma, Renal Cell | 36 | 2024 | 3159 | 3.340 |
Why?
|
| Fallopian Tube Neoplasms | 15 | 2022 | 328 | 2.160 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 10 | 2023 | 491 | 2.010 |
Why?
|
| Immunohistochemistry | 53 | 2024 | 11073 | 1.820 |
Why?
|
| Teratoma | 8 | 2024 | 402 | 1.780 |
Why?
|
| Ovarian Neoplasms | 33 | 2024 | 4880 | 1.760 |
Why?
|
| Adenoma, Oxyphilic | 6 | 2024 | 148 | 1.620 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 4 | 2023 | 77 | 1.530 |
Why?
|
| Cystadenocarcinoma, Serous | 19 | 2018 | 479 | 1.530 |
Why?
|
| Urinary Bladder Neoplasms | 14 | 2024 | 2203 | 1.520 |
Why?
|
| Leiomyomatosis | 2 | 2022 | 69 | 1.510 |
Why?
|
| Adenocarcinoma | 15 | 2024 | 6328 | 1.260 |
Why?
|
| Genital Neoplasms, Female | 5 | 2021 | 532 | 1.200 |
Why?
|
| Paired Box Transcription Factors | 5 | 2013 | 206 | 1.200 |
Why?
|
| Uterine Neoplasms | 6 | 2023 | 1420 | 1.160 |
Why?
|
| Paget Disease, Extramammary | 2 | 2023 | 51 | 1.130 |
Why?
|
| Prostatic Neoplasms | 25 | 2023 | 11089 | 1.110 |
Why?
|
| Carcinoma, Transitional Cell | 7 | 2024 | 779 | 1.020 |
Why?
|
| Kidney Medulla | 3 | 2021 | 169 | 1.010 |
Why?
|
| SOXD Transcription Factors | 2 | 2022 | 44 | 0.990 |
Why?
|
| Endodermal Sinus Tumor | 2 | 2022 | 53 | 0.990 |
Why?
|
| GATA3 Transcription Factor | 2 | 2015 | 152 | 0.960 |
Why?
|
| SOXF Transcription Factors | 1 | 2024 | 31 | 0.960 |
Why?
|
| Carcinoma | 8 | 2022 | 2328 | 0.940 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 3 | 2022 | 194 | 0.930 |
Why?
|
| Diagnosis, Differential | 28 | 2024 | 12967 | 0.900 |
Why?
|
| Metaplasia | 3 | 2021 | 321 | 0.890 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 2 | 2021 | 43 | 0.870 |
Why?
|
| Antigens, Neoplasm | 3 | 2020 | 1994 | 0.850 |
Why?
|
| Adenomatoid Tumor | 1 | 2022 | 12 | 0.810 |
Why?
|
| Sarcoma | 6 | 2023 | 1791 | 0.810 |
Why?
|
| Smooth Muscle Tumor | 2 | 2020 | 63 | 0.780 |
Why?
|
| Epithelioid Cells | 1 | 2022 | 60 | 0.780 |
Why?
|
| Peritoneal Neoplasms | 4 | 2022 | 711 | 0.780 |
Why?
|
| Catenins | 1 | 2021 | 44 | 0.770 |
Why?
|
| Seminal Vesicles | 1 | 2021 | 103 | 0.760 |
Why?
|
| Endometrial Neoplasms | 7 | 2024 | 1356 | 0.730 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2020 | 74 | 0.730 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2021 | 517 | 0.730 |
Why?
|
| Chromosomes, Human, X | 4 | 2015 | 321 | 0.730 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2021 | 549 | 0.710 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 5 | 2022 | 316 | 0.700 |
Why?
|
| Carcinoma, Papillary | 3 | 2021 | 784 | 0.670 |
Why?
|
| In Situ Hybridization, Fluorescence | 8 | 2024 | 2510 | 0.670 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2024 | 2016 | 0.670 |
Why?
|
| Urothelium | 1 | 2021 | 269 | 0.660 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2013 | 384 | 0.660 |
Why?
|
| Stathmin | 3 | 2015 | 70 | 0.630 |
Why?
|
| Urethra | 1 | 2020 | 404 | 0.610 |
Why?
|
| Ganglioneuroma | 1 | 2018 | 53 | 0.610 |
Why?
|
| Plasma Cells | 1 | 2021 | 599 | 0.590 |
Why?
|
| Translocation, Genetic | 6 | 2015 | 1387 | 0.590 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 3 | 2024 | 118 | 0.580 |
Why?
|
| Wolffian Ducts | 2 | 2018 | 27 | 0.560 |
Why?
|
| Carcinoma in Situ | 6 | 2022 | 791 | 0.540 |
Why?
|
| Precancerous Conditions | 5 | 2021 | 978 | 0.540 |
Why?
|
| Fumarate Hydratase | 3 | 2022 | 52 | 0.530 |
Why?
|
| Angiomyolipoma | 1 | 2017 | 186 | 0.530 |
Why?
|
| Terminology as Topic | 4 | 2021 | 1533 | 0.520 |
Why?
|
| Oncogenes | 4 | 2023 | 1223 | 0.510 |
Why?
|
| Male Urogenital Diseases | 1 | 2015 | 48 | 0.510 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2015 | 27 | 0.500 |
Why?
|
| Predictive Value of Tests | 18 | 2022 | 15252 | 0.500 |
Why?
|
| Female Urogenital Diseases | 1 | 2015 | 57 | 0.500 |
Why?
|
| Humans | 169 | 2024 | 760239 | 0.500 |
Why?
|
| Urinary Bladder | 2 | 2020 | 1150 | 0.490 |
Why?
|
| Radiotherapy | 1 | 2021 | 1498 | 0.470 |
Why?
|
| Adenoma | 3 | 2021 | 2156 | 0.460 |
Why?
|
| Prostate | 9 | 2022 | 1765 | 0.460 |
Why?
|
| Repressor Proteins | 2 | 2023 | 2979 | 0.450 |
Why?
|
| Carcinoma, Endometrioid | 3 | 2014 | 276 | 0.450 |
Why?
|
| Neoplasm Proteins | 4 | 2021 | 3611 | 0.440 |
Why?
|
| Trophoblasts | 1 | 2015 | 224 | 0.440 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2021 | 696 | 0.420 |
Why?
|
| Pelvic Neoplasms | 4 | 2023 | 247 | 0.410 |
Why?
|
| Sertoli Cell Tumor | 2 | 2023 | 36 | 0.410 |
Why?
|
| Female | 95 | 2024 | 391766 | 0.400 |
Why?
|
| Neoplasm Invasiveness | 8 | 2024 | 3586 | 0.400 |
Why?
|
| Neoplastic Syndromes, Hereditary | 3 | 2024 | 244 | 0.390 |
Why?
|
| Adipose Tissue | 1 | 2024 | 3305 | 0.390 |
Why?
|
| Male | 84 | 2024 | 359943 | 0.390 |
Why?
|
| Seminoma | 2 | 2023 | 134 | 0.380 |
Why?
|
| Mesonephroma | 2 | 2024 | 21 | 0.370 |
Why?
|
| Prostatectomy | 8 | 2022 | 1821 | 0.360 |
Why?
|
| Carcinoma, Medullary | 2 | 2017 | 115 | 0.360 |
Why?
|
| Lymphoma, T-Cell | 1 | 2012 | 304 | 0.350 |
Why?
|
| Fallopian Tubes | 5 | 2023 | 177 | 0.340 |
Why?
|
| Aged | 58 | 2024 | 168773 | 0.330 |
Why?
|
| Testis | 2 | 2024 | 794 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2009 | 410 | 0.330 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2022 | 339 | 0.320 |
Why?
|
| Melanoma | 3 | 2023 | 5704 | 0.320 |
Why?
|
| Vulvar Neoplasms | 2 | 2008 | 263 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2022 | 8522 | 0.310 |
Why?
|
| Mutation | 22 | 2024 | 30025 | 0.300 |
Why?
|
| Pathology | 2 | 2021 | 270 | 0.290 |
Why?
|
| Tumor Suppressor Protein p53 | 12 | 2022 | 2911 | 0.290 |
Why?
|
| Biopsy | 12 | 2023 | 6765 | 0.290 |
Why?
|
| Middle Aged | 58 | 2024 | 220307 | 0.280 |
Why?
|
| Pyrroles | 2 | 2010 | 1126 | 0.270 |
Why?
|
| Adult | 45 | 2024 | 220718 | 0.270 |
Why?
|
| Skin Neoplasms | 3 | 2022 | 5815 | 0.260 |
Why?
|
| Neuroendocrine Tumors | 2 | 2023 | 642 | 0.260 |
Why?
|
| Lymphoma, B-Cell | 1 | 2012 | 940 | 0.260 |
Why?
|
| Kidney Tubules, Collecting | 2 | 2018 | 162 | 0.260 |
Why?
|
| Hysterectomy | 2 | 2010 | 857 | 0.260 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2016 | 487 | 0.250 |
Why?
|
| Pleural Neoplasms | 1 | 2010 | 609 | 0.250 |
Why?
|
| Cell Proliferation | 11 | 2022 | 10430 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2020 | 4024 | 0.240 |
Why?
|
| Granulosa Cell Tumor | 2 | 2024 | 77 | 0.240 |
Why?
|
| Indoles | 2 | 2010 | 1832 | 0.240 |
Why?
|
| Prostate-Specific Antigen | 7 | 2022 | 2464 | 0.240 |
Why?
|
| Antineoplastic Agents | 6 | 2015 | 13618 | 0.240 |
Why?
|
| Blood Vessels | 1 | 2010 | 1113 | 0.230 |
Why?
|
| Lymph Nodes | 2 | 2015 | 3468 | 0.230 |
Why?
|
| Aged, 80 and over | 22 | 2024 | 58838 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 7379 | 0.230 |
Why?
|
| Mesothelioma | 1 | 2010 | 807 | 0.220 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2023 | 1154 | 0.220 |
Why?
|
| Blotting, Western | 4 | 2015 | 5034 | 0.220 |
Why?
|
| Neoplasms, Second Primary | 2 | 2008 | 1051 | 0.210 |
Why?
|
| beta Catenin | 2 | 2021 | 1044 | 0.210 |
Why?
|
| Malacoplakia | 1 | 2022 | 14 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2008 | 321 | 0.210 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2023 | 34 | 0.210 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2022 | 28 | 0.200 |
Why?
|
| DNA Mutational Analysis | 6 | 2018 | 4108 | 0.200 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIalpha Subunit | 1 | 2022 | 24 | 0.200 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2014 | 2821 | 0.200 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2022 | 455 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 9265 | 0.190 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2022 | 168 | 0.190 |
Why?
|
| Spermatogonia | 1 | 2021 | 30 | 0.190 |
Why?
|
| Granular Cell Tumor | 1 | 2021 | 48 | 0.190 |
Why?
|
| Leydig Cell Tumor | 1 | 2021 | 28 | 0.190 |
Why?
|
| Artifacts | 1 | 2010 | 1895 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2002 | 373 | 0.190 |
Why?
|
| Genes, BRCA2 | 4 | 2013 | 602 | 0.190 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2010 | 590 | 0.190 |
Why?
|
| Vulvar Diseases | 1 | 2021 | 62 | 0.190 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2020 | 38 | 0.190 |
Why?
|
| MART-1 Antigen | 1 | 2020 | 65 | 0.180 |
Why?
|
| Genes, BRCA1 | 4 | 2013 | 765 | 0.180 |
Why?
|
| Chorionic Gonadotropin | 1 | 2023 | 457 | 0.180 |
Why?
|
| Laryngeal Neoplasms | 1 | 2004 | 514 | 0.180 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2018 | 1741 | 0.180 |
Why?
|
| Birt-Hogg-Dube Syndrome | 1 | 2020 | 40 | 0.180 |
Why?
|
| Uterine Cervical Diseases | 1 | 2020 | 73 | 0.170 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2020 | 67 | 0.170 |
Why?
|
| Receptors, Somatostatin | 1 | 2020 | 136 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2024 | 105 | 0.170 |
Why?
|
| Carcinoma, Ductal | 1 | 2020 | 97 | 0.170 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2022 | 259 | 0.170 |
Why?
|
| Cell Differentiation | 5 | 2021 | 11527 | 0.170 |
Why?
|
| Vaginal Diseases | 1 | 2020 | 103 | 0.170 |
Why?
|
| Colorectal Neoplasms | 4 | 2024 | 6890 | 0.170 |
Why?
|
| Cell Nucleus | 3 | 2021 | 2907 | 0.160 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2021 | 3632 | 0.160 |
Why?
|
| Rhabdoid Tumor | 1 | 2021 | 210 | 0.160 |
Why?
|
| Succinate Dehydrogenase | 2 | 2021 | 145 | 0.160 |
Why?
|
| Kallikreins | 1 | 2020 | 220 | 0.160 |
Why?
|
| Choristoma | 1 | 2020 | 206 | 0.160 |
Why?
|
| Tissue Array Analysis | 4 | 2016 | 550 | 0.160 |
Why?
|
| Neoplasm Staging | 10 | 2021 | 11095 | 0.150 |
Why?
|
| Smad4 Protein | 1 | 2019 | 191 | 0.150 |
Why?
|
| Chromosome Aberrations | 3 | 2024 | 1771 | 0.150 |
Why?
|
| Urology | 2 | 2020 | 400 | 0.150 |
Why?
|
| Reproducibility of Results | 8 | 2023 | 20076 | 0.150 |
Why?
|
| Retrospective Studies | 19 | 2024 | 80414 | 0.150 |
Why?
|
| Gadolinium DTPA | 3 | 2017 | 823 | 0.150 |
Why?
|
| Alphapapillomavirus | 1 | 2020 | 218 | 0.140 |
Why?
|
| Thyroid Gland | 1 | 2004 | 1168 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2022 | 2806 | 0.140 |
Why?
|
| Gene Expression Profiling | 8 | 2021 | 9415 | 0.140 |
Why?
|
| 5-Methylcytosine | 1 | 2017 | 147 | 0.140 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2021 | 617 | 0.140 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2017 | 35 | 0.140 |
Why?
|
| Gene Amplification | 4 | 2014 | 1086 | 0.140 |
Why?
|
| Cadherins | 1 | 2021 | 905 | 0.140 |
Why?
|
| Ki-67 Antigen | 3 | 2015 | 629 | 0.140 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2022 | 1604 | 0.140 |
Why?
|
| Sarcoidosis | 1 | 2022 | 521 | 0.130 |
Why?
|
| Saposins | 1 | 2016 | 26 | 0.130 |
Why?
|
| Northern Ireland | 1 | 2015 | 37 | 0.130 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 1125 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 2820 | 0.130 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 2218 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2019 | 952 | 0.120 |
Why?
|
| Histone Code | 1 | 2016 | 158 | 0.120 |
Why?
|
| Specialization | 1 | 2020 | 778 | 0.120 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2015 | 92 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2021 | 611 | 0.120 |
Why?
|
| Disease Progression | 6 | 2020 | 13483 | 0.120 |
Why?
|
| Germ Cells | 1 | 2018 | 634 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2024 | 36351 | 0.120 |
Why?
|
| Karyotyping | 2 | 2009 | 1171 | 0.120 |
Why?
|
| Urogenital Neoplasms | 1 | 2015 | 129 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 11729 | 0.120 |
Why?
|
| S100 Proteins | 1 | 2015 | 218 | 0.120 |
Why?
|
| Thrombospondin 1 | 1 | 2016 | 257 | 0.120 |
Why?
|
| Biological Products | 1 | 2023 | 911 | 0.120 |
Why?
|
| Papillomavirus Infections | 2 | 2020 | 1610 | 0.120 |
Why?
|
| Keratin-7 | 2 | 2017 | 55 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2023 | 2058 | 0.110 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 1407 | 0.110 |
Why?
|
| Ubiquitination | 1 | 2018 | 1007 | 0.110 |
Why?
|
| Health Resources | 1 | 2020 | 935 | 0.110 |
Why?
|
| Peptides, Cyclic | 1 | 2016 | 392 | 0.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2015 | 2052 | 0.110 |
Why?
|
| Ovary | 1 | 2018 | 958 | 0.110 |
Why?
|
| Leuprolide | 1 | 2015 | 311 | 0.110 |
Why?
|
| Meningioma | 1 | 2022 | 1218 | 0.110 |
Why?
|
| Octamer Transcription Factor-3 | 2 | 2016 | 223 | 0.110 |
Why?
|
| Cyclin E | 1 | 2013 | 156 | 0.110 |
Why?
|
| Observer Variation | 5 | 2021 | 2604 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2015 | 636 | 0.110 |
Why?
|
| Prognosis | 12 | 2019 | 29547 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2022 | 1248 | 0.110 |
Why?
|
| Protective Agents | 1 | 2014 | 150 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 3 | 2020 | 9176 | 0.110 |
Why?
|
| Calcinosis | 1 | 2022 | 1469 | 0.110 |
Why?
|
| Young Adult | 13 | 2022 | 59054 | 0.110 |
Why?
|
| Inhibitor of Differentiation Proteins | 1 | 2012 | 17 | 0.110 |
Why?
|
| Genes, erbB-1 | 1 | 2013 | 162 | 0.100 |
Why?
|
| Cell Lineage | 2 | 2018 | 2539 | 0.100 |
Why?
|
| Isoenzymes | 1 | 2017 | 1688 | 0.100 |
Why?
|
| Protein Kinase C | 1 | 2017 | 1202 | 0.100 |
Why?
|
| Racemases and Epimerases | 2 | 2021 | 114 | 0.100 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 14661 | 0.100 |
Why?
|
| Antigens, CD | 2 | 2021 | 4000 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 3 | 2010 | 1704 | 0.100 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2014 | 629 | 0.090 |
Why?
|
| Gene Order | 1 | 2011 | 169 | 0.090 |
Why?
|
| Intestines | 1 | 2020 | 1908 | 0.090 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 2912 | 0.090 |
Why?
|
| Cell Line, Tumor | 7 | 2016 | 16948 | 0.090 |
Why?
|
| Pelvis | 1 | 2015 | 732 | 0.090 |
Why?
|
| Risk Assessment | 7 | 2021 | 23942 | 0.090 |
Why?
|
| Nuclear Proteins | 2 | 2009 | 5789 | 0.090 |
Why?
|
| Carcinoma, Islet Cell | 1 | 2010 | 21 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 4574 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 1347 | 0.090 |
Why?
|
| Adenoma, Islet Cell | 1 | 2010 | 72 | 0.090 |
Why?
|
| Biopsy, Needle | 3 | 2021 | 1626 | 0.090 |
Why?
|
| Transcription Factors | 4 | 2023 | 12113 | 0.090 |
Why?
|
| Epithelial Cells | 2 | 2020 | 3667 | 0.090 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2010 | 66 | 0.090 |
Why?
|
| Receptor, Notch1 | 1 | 2013 | 496 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2020 | 1909 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 1427 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2020 | 1649 | 0.090 |
Why?
|
| Appendectomy | 1 | 2013 | 433 | 0.090 |
Why?
|
| Elafin | 1 | 2010 | 31 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 5291 | 0.090 |
Why?
|
| Phenotype | 8 | 2022 | 16588 | 0.090 |
Why?
|
| Tumor Microenvironment | 3 | 2021 | 3874 | 0.090 |
Why?
|
| Oncogene Proteins | 1 | 2013 | 719 | 0.080 |
Why?
|
| Cystectomy | 1 | 2014 | 631 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2014 | 2859 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1089 | 0.080 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 1365 | 0.080 |
Why?
|
| Neoplasm Metastasis | 4 | 2016 | 4902 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 1889 | 0.080 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 897 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2021 | 3903 | 0.080 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2010 | 232 | 0.080 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2012 | 332 | 0.080 |
Why?
|
| Keratin-19 | 1 | 2008 | 33 | 0.080 |
Why?
|
| HLA-D Antigens | 1 | 2008 | 134 | 0.080 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2010 | 1304 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2019 | 6472 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2012 | 570 | 0.080 |
Why?
|
| Carcinoid Tumor | 1 | 2010 | 224 | 0.080 |
Why?
|
| Loss of Heterozygosity | 2 | 2023 | 659 | 0.080 |
Why?
|
| Histones | 1 | 2018 | 2579 | 0.080 |
Why?
|
| Ascites | 1 | 2010 | 338 | 0.080 |
Why?
|
| Laparoscopy | 2 | 2010 | 2035 | 0.080 |
Why?
|
| SEER Program | 1 | 2013 | 1449 | 0.080 |
Why?
|
| Watchful Waiting | 1 | 2012 | 491 | 0.080 |
Why?
|
| Nephrectomy | 4 | 2017 | 934 | 0.080 |
Why?
|
| Immune Tolerance | 1 | 2017 | 2300 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 2 | 2013 | 1343 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2017 | 2788 | 0.070 |
Why?
|
| Health Care Surveys | 3 | 2021 | 2424 | 0.070 |
Why?
|
| Vulva | 1 | 2008 | 82 | 0.070 |
Why?
|
| Treatment Outcome | 12 | 2020 | 64583 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2023 | 430 | 0.070 |
Why?
|
| Contrast Media | 5 | 2024 | 5309 | 0.070 |
Why?
|
| Genes, p53 | 4 | 2013 | 712 | 0.070 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2009 | 286 | 0.070 |
Why?
|
| Genomics | 5 | 2023 | 5807 | 0.070 |
Why?
|
| Child | 10 | 2022 | 80070 | 0.070 |
Why?
|
| Sex Factors | 1 | 2021 | 10534 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2024 | 20550 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2017 | 2898 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 5358 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 3783 | 0.070 |
Why?
|
| Boston | 3 | 2015 | 9324 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2804 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2017 | 1766 | 0.070 |
Why?
|
| Chromatin | 1 | 2018 | 2951 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2021 | 17859 | 0.070 |
Why?
|
| Vaginal Neoplasms | 1 | 2007 | 104 | 0.070 |
Why?
|
| Hernia, Ventral | 1 | 2010 | 218 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 931 | 0.070 |
Why?
|
| Cervix Uteri | 1 | 2010 | 570 | 0.070 |
Why?
|
| Gene Frequency | 1 | 2013 | 3638 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2022 | 7944 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2016 | 12787 | 0.060 |
Why?
|
| Time Factors | 6 | 2020 | 39928 | 0.060 |
Why?
|
| Nevus, Pigmented | 1 | 2008 | 221 | 0.060 |
Why?
|
| Risk Factors | 8 | 2021 | 73999 | 0.060 |
Why?
|
| Microtubules | 1 | 2011 | 1074 | 0.060 |
Why?
|
| Brain Neoplasms | 2 | 2024 | 9003 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2021 | 10074 | 0.060 |
Why?
|
| Organ Size | 1 | 2010 | 2252 | 0.060 |
Why?
|
| Receptors, Progesterone | 1 | 2009 | 1126 | 0.060 |
Why?
|
| Corpus Luteum | 1 | 2004 | 81 | 0.060 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2004 | 81 | 0.060 |
Why?
|
| Muscle Proteins | 1 | 2009 | 1152 | 0.060 |
Why?
|
| Genotype | 3 | 2013 | 12971 | 0.060 |
Why?
|
| Androgens | 2 | 2023 | 1282 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2016 | 3486 | 0.060 |
Why?
|
| Genomic Instability | 1 | 2008 | 709 | 0.060 |
Why?
|
| Homeodomain Proteins | 2 | 2012 | 2412 | 0.060 |
Why?
|
| Chromosome Duplication | 1 | 2023 | 75 | 0.060 |
Why?
|
| Apoptosis | 3 | 2018 | 9469 | 0.060 |
Why?
|
| Genome, Human | 1 | 2016 | 4423 | 0.060 |
Why?
|
| Signal Transduction | 7 | 2021 | 23405 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2013 | 2213 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 2722 | 0.050 |
Why?
|
| Epithelium | 3 | 2013 | 1605 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 3429 | 0.050 |
Why?
|
| Robotics | 1 | 2010 | 819 | 0.050 |
Why?
|
| Calcitonin | 1 | 2004 | 329 | 0.050 |
Why?
|
| Mitochondria | 2 | 2016 | 3625 | 0.050 |
Why?
|
| Methotrexate | 2 | 2023 | 1720 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 3345 | 0.050 |
Why?
|
| Medical Errors | 1 | 2010 | 1260 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 197 | 0.050 |
Why?
|
| Orchiectomy | 1 | 2024 | 463 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2009 | 2201 | 0.050 |
Why?
|
| Neurofibromin 2 | 1 | 2022 | 270 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2010 | 2485 | 0.050 |
Why?
|
| Nucleotides | 1 | 2023 | 453 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2012 | 2517 | 0.050 |
Why?
|
| Specimen Handling | 2 | 2020 | 703 | 0.050 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2023 | 330 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2024 | 733 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2012 | 1955 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 6812 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2023 | 371 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2016 | 856 | 0.040 |
Why?
|
| Neprilysin | 1 | 2003 | 473 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 2167 | 0.040 |
Why?
|
| Keratins | 1 | 2021 | 497 | 0.040 |
Why?
|
| Granuloma | 1 | 2022 | 327 | 0.040 |
Why?
|
| Adnexa Uteri | 1 | 2019 | 40 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 2019 | 0.040 |
Why?
|
| Telomerase | 1 | 2024 | 745 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2022 | 354 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2009 | 2553 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 428 | 0.040 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 2015 | 0.040 |
Why?
|
| Alleles | 3 | 2017 | 6905 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2022 | 551 | 0.040 |
Why?
|
| Adolescent | 8 | 2022 | 88173 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2018 | 6129 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 39067 | 0.040 |
Why?
|
| Models, Biological | 1 | 2015 | 9461 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 3592 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2015 | 41340 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2021 | 1153 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 557 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2015 | 1887 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 3705 | 0.040 |
Why?
|